Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27152308
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27152308
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Menopausal+Med
2016 ; 22
(1
): 9-13
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Flibanserin for Treating Hypoactive Sexual Desire Disorder
#MMPMID27152308
Sang JH
; Kim TH
; Kim SA
J Menopausal Med
2016[Apr]; 22
(1
): 9-13
PMID27152308
show ga
There have been several products developed for male sexual dysfunction. However,
developing agents for female sexual dysfunction is lagging behind for various
reasons. Sildenafil citrate (Viagra) and Tadalafil (Cialis), which have been
prescribed for male sexual function disorders, are known to act on vessels.[1] On
the other hand, flibanserin is thought to act on brain. Flibanserin has been
approved by U. S. Food and Drug Administration (FDA) for treatment of hypoactive
sexual desire disorder (HSDD) of premenopausal women in 2015, and is expected to
be released in South Korea soon. Authors wrote this article to acknowledge
flibanserin to sexologists for females or physicians for menopausal medicine, so
that this agent can be safely used for females who have HSDD.